225 NE MIZNER BLVD, SUITE 640, BOCA RATON, FL
Warrant Inducement Offer Agreement with Holders of April 2024 Warrants
Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
Stockholders Approve Amended 2021 Stock Incentive Plan with Share Increase
Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer’s Trial
Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer’s Disease
Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
Modulating the Innate Immune System to Transform Inflammation - Driven Disease 1 Corporate Presentation March 2025
Other Events
Q1
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration of Securities
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement
Schedule 13G - Ownership Report
Correspondence